Table 1.
Characteristics of the studies included in the review
| (a) Study | Phase | Level evidence | Median follow-up, months (range) | Patients (n) | Risk group, n (%) | ADT (%) | Outcomes | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low | Intermediate | High | Toxicity | PRO | BFS | Other oncologic outcomes | ||||||
| Miralbell 2010 [7] | 2 | 2 | 63 (18–88) | 50 | 5 (10) | 12 (24) | 33 (66) | 66 | Yes | No | Yes | Yes |
| Buwenge 2020 [8] | 2 | 2 | 120 (25–150) | 44 | 6 (13.6) | 18 (40.9) | 20 (45.5) | 100 | Yes | No | Yes | Yes |
| FLAME Kerkmeijer 2021 [10] and Groen 2022 [14] | 3 | 1 | 72 (58–86) |
Focal Boost: 284 Standard: 287 |
2 (1) | 43 (15) | 239 (84) | 60 | Yes | Yes | Yes | Yes |
| 2SMART Ong 2023 [16] | 2 | 2 | 44 (NR) | 30 | 2 (7) | 28 (93) | 0 | 7 | Yes | Yes | Yes | Yes |
| Cloitre 2023 [15] | 2 | 2 | 61 (42–110) | 33 | 1 (3) | 14 (42) | 18 (55) | 3 | Yes | Yes | Yes | No |
| Maas 2023 [17] | 2 | 2 | 59.5 (11–86) | 26 | 6 (8) | 20 (92) | 0 | 27 | Yes | Yes | Yes | No |
| DELINEATE Tree 2023 [12] | 2 | 2 | > 60 (NR) | 256 | 0 | 111 (43) | 145 (57) | 100 | Yes | Yes | Yes | No |
| (b) Study | Treatment planning characteristics | Toxicity outcomes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose (Gy) | Fractionation | Boost type | IPL Boost Dose (Gy) | GTVIPL-PTVIPL margins (mm) | Urethra Dose constraint | Acute (% of patients) | Late (% of patients) | |||||||
| GU | GI | GU | GI | |||||||||||
| G2 + | G3 + | G2 + | G3 + | G2 + | G3 + | G2 + | G3 + | |||||||
| Miralbell 2010 [7] | 64 | 32 | Sequential—3dCF followed by IMRT boost | 74–80 | NR | Yes—Not Reported | 50 | 13 | 8 | 0 | 12 | 0 | 20 | 10 |
| Buwenge 2020 [8] | 72 | 40 | SIB | 80 | 15: GTVIPL + 5 = CTVIPL + 10 = PTVIPL | NR | NR | NR | NR | NR | NR | 4.5 | NR | 2.3 |
| FLAME Kerkmeijer 2021 [10] & Groen 2022 [14] | 77 | 35 | SIB | 95 | 0 | None | NR | NR | NR | NR | 27.8 | 5.6 | 12.7 | 1.4 |
| 2SMART Ong 2023 [16] | 26 | 2 | SIB | 32 | 0 | Yes—Not Reported | 56 | 0 | 3 | 0 | 50 | 0 | 10 | 0 |
| Cloitre 2023 [15] | 36.25 | 5 | SIB | 45–50 | 3 |
D1cc < 39 Gy D0.1 cc < 41 Gy |
15 | 0 | 6 | 0 | 12 | 0 | 3 | 0 |
| Maas 2023 [17] | 36.25 | 5 | SIB | 40 | 0–5 | Dmax < 38.78 Gy | 42 | 0 | 4 | 0 | 39 | 0 | 11.5 | 0 |
| DELINEATE Tree 2023 [12] |
A: 74 B: 60 C: 74 |
A: 37 B: 20 C: 37 |
SIB |
A: 82 B: 67 C: 82 |
2 |
A: D2% < 83 Gy B: D2% < 67.3 Gy C: D2% < 83 Gy |
A: 38 B: 36 C: 38 |
NR |
A: 11 B: 14 C: 15 |
NR |
A: 13 B: 18 C:18 |
A: 4 B: 2 C: 3 |
A: 13 B: 15 C: 21 |
A: 0 B: 1 C: 3 |